Background: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is fatal as a result of primary refractoriness, relapse, and treatment-related mortality. Although the majority of patients with AML enter remission upon induction chemotherapy, the risk of relapse is considerable.
Aim of the Work: To evaluate ADAM28 expression in newly diagnosed adult Egyptian Acute Myeloid Leukemia patients and to assess its impact on outcome
Patients and Methods: This was a prospective case control study was conducted at Ain Shams university hospitals. Clinical hematology division of internal medicine department including 60 participants: 30 adult patients with newly diagnosed AML and 30 healthy age and sex matched control. The duration of the study was 6 months.
Results: The main findings of the study revealed that: There was no statistically significant difference between the studied groups as regard demographic data, according to FAB score there were 8 (26.7%) M1, 10 (33.3%) M2, 8 (26.7%) M3 and 4 (13.3%) M4, there was high statistically significant difference between the studied groups as regard WBCs, Plts and ESR and statistically significant difference as regard Hb, there was no statistically significant difference between the studied groups as regard Liver and kidney function tests, according to Cytogenetic risk category there were 4 (13.3%) favorable, 18 (60%) intermediate and 8 (26.7%) unfavorable, there was high statistically significant difference between the studied groups as regard ADAM-28m and ADAM-28s,    according to response to chemotherapy in the induction phase  there were 13 patients in remission and 11 patients did not respond to chemotherapy and there were 6 who died .
Conclusion: There was high statistically significant difference between the studied groups as regard ADAM-28m and ADAM-28s. There was significant correlation between ADAM-28 and response to chemotherapy. ADAM28 improved the growth and dissemination of AML.